Natural History of Dilated Cardiomyopathy in Children by Puggia, Ilaria et al.
Natural History of Dilated Cardiomyopathy in Children
Ilaria Puggia, MD; Marco Merlo, MD; Giulia Barbati, PhD; Teisha J. Rowland, PhD; Davide Stolfo, MD; Marta Gigli, MD; Federica Ramani, PhD;
Andrea Di Lenarda, MD; Luisa Mestroni, MD, FACC, FESC; Gianfranco Sinagra, MD, FESC
Background-—The long-term progression of idiopathic dilated cardiomyopathy (DCM) in pediatric patients compared with adult
patients has not been previously characterized. In this study, we compared outcome and long-term progression of pediatric and
adult DCM populations.
Methods and Results-—Between 1988 and 2014, 927 DCM patients were consecutively enrolled. The pediatric population
(aged <18 years at enrollment) included 47 participants (5.1%). At presentation, the pediatric population compared with adult
patients had a signiﬁcantly increased occurrence of familial forms (P=0.03), shorter duration of heart failure (P=0.04), lower
systolic blood pressure (P=0.01), decreased presence of left bundle-branch block (P=0.001), and increased left ventricular
ejection fraction (P=0.03). Despite these baseline differences, long-term longitudinal trends of New York Heart Association
class III to IV, left ventricular dimensions, left ventricular ejection fraction, and restrictive ﬁlling pattern were similar between
the 2 populations. Regarding survival analysis, because of the size difference between the 2 populations, we compared the
pediatric population with a sample of adult patients randomly matched using the above-mentioned baseline differences in a
3:1 ratio (141 adult versus 47 pediatric patients). During a median follow-up of 110 months, survival free from heart
transplantation was signiﬁcantly lower among pediatric patients compared with adults (P<0.001). Furthermore, pediatric age
(ie, <18 years) was found to be associated with an increasing risk of both death from pump failure and life-threatening
arrhythmias.
Conclusions-—Despite the pediatric DCM population having higher baseline left ventricular ejection fraction and similar long-term
echocardiographic progression compared with the adult DCM population, the pediatric DCM patients had worse cardiovascular
prognosis. ( J Am Heart Assoc. 2016;5:e003450 doi: 10.1161/JAHA.116.003450)
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I diopathic dilated cardiomyopathy (DCM) is a heart muscledisorder characterized by systolic dysfunction and dilation
of the left or both ventricles in the absence of any other
possible cause.1 DCM can develop in people of any age or
ethnicity, although it is more common in male than female
persons (occurring at a ratio of 3:1 in male to female
persons) and typically manifests in the third to fourth decades
of life.2,3 DCM is the predominant cause of cardiomyopathy in
both adult and pediatric populations.3,4 In adults, DCM has an
estimated prevalence of 1:2500.3 In contrast, annual inci-
dence in pediatric populations has been reported to be much
lower: 1:170 000 in the United States5 and 1:140 000 in
Australia.6
Although pediatric DCM has a lower annual incidence than
adult DCM, the outcome for pediatric DCM patients is
particularly severe.7–9 DCM is the most frequent cause of
heart transplantation (HTx) in pediatric patients.10 Data from
international pediatric DCM registries indicate that the rates
of death or HTx over 1- and 5-year periods were 31% and 46%,
respectively.4 Conversely, recent data showed that the HTx-
free survival rate in adult DCM patients receiving optimal
treatment is >85% at 8 years.2
Comparative studies between pediatric and adult DCM
populations are currently lacking in the literature. This is
clinically relevant. In fact, because of the difﬁculty of
performing controlled clinical trials with pediatric populations,
the number of such trials has been limited.10 Consequently,
the treatment strategies used for pediatric DCM patients have
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been extrapolated primarily from data based on clinical trials
using adult DCM patients. By better characterizing the
baseline and long-term progression and outcome of pediatric
DCM patients in comparison to adult DCM patients, for which
ample data have already been collected, it is thought that
improved treatment strategies could be developed for pedi-
atric patients.
The aim of this study was to provide insights into the long-
term characterization and outcome of DCM in a pediatric
population compared with an adult one to ultimately improve
the clinical management of DCM in children.
Methods
Study Population
We analyzed data from all DCM patients that had consecu-
tively enrolled in the Trieste Heart Muscle Disease Registry in
Italy between 1988 and 2014, according to the protocol
approved by the institutional review board of the Trieste
Hospital administration and the local ethics committee.
Informed consent was obtained from all participants. The
investigation was in line with the principles outlined in the
Declaration of Helsinki.11
The diagnosis of DCM was assigned according to the
current guidelines.1,12,13 We excluded patients with a sec-
ondary cause of myocardial damage, including coronary artery
disease (investigated with coronary angiography/computed
tomography), hypertensive disorder, valvular disease, biopsy-
proven active myocarditis, associated congenital heart dis-
ease, history of chemotherapy or pharmacologic cardiotoxi-
city, pulmonary parenchymal or vascular disease,
immunological disease, and mitochondrial disease (studied
by complete neurological examination, plasma lactate and
amino acids, urine amino and organic acids, and pyruvate and
acylcarnitine proﬁles, if indicated).2 Neuromuscular disease
was investigated with a laboratory test (ie, creatine kinase)
and electromyography and, for ﬁnal diagnosis, by skeletal
muscle biopsy if clinically indicated. In the absence of family
history of DCM and in the presence of severe recent-onset
heart failure (HF), all pediatric patients underwent endomy-
ocardial biopsy and, from 2010, cardiac magnetic resonance
to exclude active myocarditis. At enrollment, all patients
underwent an initial screening that included a detailed clinical
and family history interview, a complete clinical examination,
an electrocardiogram, 24-hour Holter monitoring, and a
comprehensive echocardiographic evaluation. Conventional
2-dimensional echocardiographic M-mode pulsed Doppler and
tissue Doppler imaging were all performed according to
international guidelines.14,15 After enrollment, if not con-
traindicated, all patients received standard medical therapy
with angiotensin-converting enzyme inhibitors, angiotensin
receptor blockers, and beta blockers titrated to the highest
tolerated dose. Clinical and instrumental data were recorded
at enrollment and then after 6 months (range 3–8 months),
12 months (range 9–18 months), and 24 months (range 19–
36 months) in follow-up evaluations. At >24 months after
enrollment, patients were recorded at least once every
2 years. Patients who were aged ≤18 years at enrollment
were considered part of the pediatric population.6,16 To
improve the accuracy of our comparisons between 2 differ-
ently sized populations, prognostic assessment statistics
compared the pediatric population with a sample of adult
controls randomly matched in a 1:3 ratio (47 pediatric
patients to 141 adult patients). This was adjusted for the most
relevant baseline differences between the 2 groups, as
explained in the “Statistical Analysis” section.
Clinical Outcomes
Three outcome measurements were primarily investigated: (1)
death or HTx, (2) sudden cardiac death or malignant
ventricular arrhythmia (MVA), and (3) death caused by pump
failure or HTx. Data were collected over follow-up periods of 1,
6, and 9 years. All patients with refractory HF requiring
inotropic treatment and/or mechanical support or with life-
threatening arrhythmias unresponsive to medical therapy
and/or catheter ablation and who did not have contraindica-
tions were listed for urgent HTx.2
Sudden death was deﬁned as immediate death occurring
within 1 hour after the onset of symptoms or during sleep in
stable patients with New York Heart Association (NYHA) class
I to III disease. MVAs were deﬁned as ventricular ﬁbrillation/
ﬂutter or sustained ventricular tachycardia (>30-second
duration of >200 beats per minute or hemodynamically
signiﬁcant), as recorded by an implantable cardioverter-
deﬁbrillator or external deﬁbrillation. Other investigated
outcomes included cardiovascular death, noncardiac death,
and death from unknown causes.
The Trieste Heart Muscle Disease Registry
The Trieste Heart Muscle Disease Registry is a local relational
database, active since 1978, that systematically collects the
data of patients affected by DCM and other cardiomyopathies
consecutively evaluated in the cardiovascular department of
the Azienda Ospedaliero-Universitaria “Ospedali Riuniti” of
Trieste. Used as a client interface, the system has all of the
characteristics of a rapid application development client/
server system. Data registration is composed of a table series
corresponding to the clinical (history, family study, clinical
examination) and instrumental evaluation (laboratory exami-
nations; electrocardiography; Holter monitoring; echocardio-
graphy; and, when indicated, cardiac catheterization and
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endomyocardial biopsy) and pharmacological therapy at
baseline and at scheduled follow-up evaluations. A section
dedicated to fatal and nonfatal events and their causes is also
present.
Statistical Analysis
Categorical data are reported as counts and percentages.
Continuous variables are presented as means and standard
deviations or medians and interquartile ranges, as appropri-
ate. For descriptive comparisons, clinical and instrumental
characteristics at baseline were compared between groups
of patients. This was achieved by 1-way ANOVA for
continuous variables or the nonparametric median test, as
necessary; for categorical variables, the chi-square or Fisher
exact test was used, as appropriate. To assess the
longitudinal changes in the investigated parameters, 2
analyses were performed. First, simple tests for repeated
consecutive measures were calculated separately for each
group (the McNemar test for binary parameters and the
paired t test for continuous parameters). Second, linear
mixed-effects models with time and group as the covariates
(in which time is the follow-up visit and group was deﬁned
as either pediatric or adult) were used to investigate whether
a different behavior was present between the groups over
time (by means of the interaction term time9group evalu-
ated in the models). For the binary parameters, generalized
linear mixed models were applied.17 Because of the size
difference between the pediatric and adult groups, we
compared the survival of the pediatric patients with that of a
sample of adult patients randomly matched in a 1:3 ratio to
increase the efﬁcacy of the survival comparison. The
matching procedure accounted for the variables that were
signiﬁcantly different at baseline between the 2 populations
and that had known possible relevance for the outcome in
DCM patients. Event-free survival curves for the 3 primarily
investigated outcomes (described in the “Clinical Outcomes”
section) were estimated and plotted using the Kaplan–Meier
method. The differences between the groups were assessed
using the log-rank test. Last, univariate and multivariate Cox
regression models were estimated in the target population
(pediatric patients). The limited sample size and number of
events in this group were taken into account using a
backward-conditional stepwise procedure to select the
subset of the most powerful independent predictors. Only
univariable hazard ratios were estimated for the secondary
end points (sudden cardiac death or malignant ventricular
arrhythmia and death from pump failure or HTx). Statistical
analyses were conducted using the IBM SPSS Statistics
version 19 (IBM Corp) and R software version 3.0.2 (R
Foundation for Statistical Computing) with the “matching”
and “rgenoud” libraries.
Results
Clinical and Echocardiographic Characterization
Of the entire population of 927 DCM patients enrolled
between 1988 and 2014, 47 (5.1%) were pediatric. The
median follow-up time after the ﬁrst clinical evaluation was
110 months (interquartile range 54–185 months). Table 1
shows the clinical data of the pediatric population at baseline
compared with the adult group.18 A family history of DCM was
Table 1. Clinical Data at Baseline for Pediatric and Adult
DCM Patients
Characteristic
Adult
Population
(n=880; 94.9%)
Pediatric
Population
(n=47; 5.1%) P Value
Male sex (%) 79.5 69.6 0.180
Age, y 4713 153 <0.001
BSA, m2 1.880.23 1.690.44 <0.001
Family history of DCM 17.5 34.8 0.03
Family history of SD 9.1 13.6 0.289
SBP, mm Hg 124.617.4 116.220.2 0.01
DBP, mm Hg 80.529.8 71.510.4 0.04
Diabetes mellitus
type 1 (%)
0.5 0 0.7
Diabetes mellitus
type 2 (%)
8.1 0 0.07
Smoking (%) 30.1 8.3 0.005
NYHA III–IV (%) 23.4 19.1 0.5
HF duration, mo,
median (IQR)
0 (0–6) 1 (0–7) 0.04
LBBB (%) 31.9 4.4 <0.001
LVEDD,* mm/m2 35.8 15.9 39.3  13.3 0.9
LVESD,* mm/m2 29.612.5 31.912.7 0.1
LVEDV, mL/m2 96.637.5 102.744.9 0.4
LVESV, mL/m2 67.934.3 69.139.8 0.3
LVEF (%) 32.310.9 36.013.2 0.03
Moderate to severe
MR (%)
33.5 25.5 0.3
Beta blockers (%) 83.3 76.7 0.26
ACEIs (%) 86.1 83.7 0.66
Digoxin (%) 54.7 55.8 0.89
Diuretics (%) 64.2 48.8 0.04
ACEI indicates angiotensin-converting enzyme inhibitor; BSA, body surface area; DCM,
dilated cardiomyopathy; DBP, diastolic blood pressure; HF, heart failure; IQR,
interquartile range; LBBB, left bundle-branch block; LVEDD, left ventricular end-diastolic
diameter; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection
fraction; LVESD, left ventricular end-systolic diameter; LVESV, left ventricular end-
systolic volume; MR mitral regurgitation; NYHA, New York Heart Association; SBP,
systolic blood pressure; SD, sudden death.
*The pediatric left ventricular diameters are represented also as z scores18: LVEDD,
z=1.87; LVESD, z=0.66.
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signiﬁcantly more common among the pediatric population
(34.8% versus 17.5%; P<0.03). The pediatric patients pre-
sented with signiﬁcantly lower systolic arterial blood pressure
(11620 versus 12517 mm Hg; P<0.01), a lower presence
of left bundle-branch block (4.4% versus 31.9%; P<0.001), and
a higher occurrence of left ventricular ejection fraction (LVEF;
3613 versus 3211; P<0.03). Pediatric patients were also
characterized by a shorter duration of HF symptoms (median
0 months [interquartile range, 1st–3rd quartiles: 0–6 months]
versus 1 month [interquartile range, 1st–3rd quartiles: 0–7
months]; P<0.04). Both groups received optimized treatments
for HF without age-related differences. Despite different
features at baseline, no signiﬁcant differences were observed
between the pediatric and adult populations regarding the
long-term longitudinal trends in NYHA functional classes III–
IV, left ventricular end-diastolic diameter and volume, LVEF,
and restrictive ﬁlling pattern. An initial improvement under
treatment, midterm stabilization, and then a subsequent trend
to progressive worsening of these parameters were observed
in the long term in both the adult and pediatric populations
(Figure 1). The matched sample was built by adjusting for
differences in familiar forms, duration of HF, systolic blood
pressure, left bundle-branch block, and LVEF; moreover, we
checked for others parameters that were different in the
original sample and found nonsigniﬁcant differences (diastolic
blood pressure in the matched sample was 7412 mm Hg in
the adult population versus 7211 mm Hg in the pediatric
patients, P=0.09; diabetes mellitus 6% versus 0%, P=0.11;
smokers 26% versus 10%, P=0.05; and diuretics 49% versus
46%, P=0.967).
Long-Term Outcomes
Table 2 shows the incidence of major events in the pediatric
population and the entire adult DCM population. The
incidence of death or HTx was signiﬁcantly higher for the
pediatric patients compared with the adults (43.5% [5 events
per 100 patients per year] versus 25.8% [3.4 events per
100 patients per year]; P<0.018). The worst outcomes for the
pediatric patients were death caused by HF or HTx (21%
[2.5 events per 100 patients per year] in pediatric patients
versus 7% [0.8 event per 100 patients per year] in adults,
P<0.001) and sudden death or MVA (21% [2.5 events per
100 patients per year] versus 14% [1.7 events per 100 pa-
tients per year], respectively; P<0.001).
Figure 2A shows that long-term survival free from death or
HTx was signiﬁcantly lower among the 47 pediatric DCM
patients compared with the matched sample of 141 adults
(P<0.001). Notably, a signiﬁcant survival difference can be
seen as early as 12 months after enrollment (survival rates at
1 year: 82% versus 98% in pediatric versus adult populations,
respectively; P<0.001). At follow-up time points of 6 and
Figure 1. Long-term longitudinal trends of clinical and echocardiographic parameters (NYHA classes III–IV class, LVEDD_I, LVEDV-I, LVEF,
RFP) in pediatric (solid line) and adult (dotted line) populations. LVEDD_I indicates indexed left ventricular end-diastolic diameter; LVEDV_I,
indexed left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; MR, mitral regurgitation; NYHA, New York Heart association;
RFP, restrictive ﬁlling pattern.
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9 years, the survival rates were 71% versus 89%, respectively,
in the pediatric patients and 68% versus 89%, respectively, in
the adult patients (P<0.0001). Similar results were obtained
when examining survival rates free from the combined end
points of sudden death or MVA and death from pump failure
or HTx (P<0.001 for both) (Figure 2B and 2C). Figure 3 shows
the effect of the age at enrollment on patient outcome, with
pediatric age (ie, <18 years) associated with a signiﬁcantly
decreased mortality rate and increased occurrence of HTx.
Finally, we performed a univariate and subsequent multi-
variate Cox analysis among the pediatric population to identify
possible prognostic indicators. We found that lower LVEF and
NYHA functional class III–IV at baseline were the most
powerful independent predictors of the occurrence of death or
HTx. Conversely, the use of beta blockers was found to be a
protective factor (Table 3). The pediatric patients received
beta blocker treatment throughout the enrollment period (ie,
beta blocker therapy before versus after the year 2000: 76%
versus 84%, P=0.421). The univariate analyses for sudden
death or MVA and for pump-failure death or HTx are reported
in Tables 4 and 5. Of note, a positive family history for DCM
emerged as the only signiﬁcant predictor (hazard ratio 3.79,
95% CI 1.224–14.7; P=0.045) for arrhythmic events in the
pediatric population (Table 5).
Discussion
Main Findings
This study compared the characterizations, long-term pro-
gression, and outcomes of adult and pediatric DCM patients.
Most studies of pediatric DCM populations have been based
on registries drawn from the United States or Australia, and
recent data on European populations, provided in this study,
have been less represented. Furthermore, in the current
literature, comparative studies of adult and pediatric DCM
patients are lacking. This issue is relevant because the
management of pediatric DCM is based largely on long-term
data derived from adult cohorts.
In this study, we reported a large and well-selected
idiopathic DCM cohort in which pediatric cases are rare,
representing only 5% of the whole population; however,
clinical cardiologists have to pay particular attention to
pediatric DCM. In fact, in our pediatric population, we saw
that the disease was less severe at baseline compared with
adults, as suggested by the lower percentage of left bundle-
branch block, the higher occurrence of LVEF, and the shorter
Table 2. Incidence of Major Cardiovascular Outcomes in
Pediatric and Adult Patients With Idiopathic Dilated
Cardiomyopathy
Outcome, n (%);
incidence (events/
100 patients/year)
Adult Population
(n=880; 94.9%)
Pediatric
Population
(n=47; 5.1%) P Value
Death or HTx 253 (25.8); 3.4 20 (42.5); 5.0 0.018
Death for refractory
HF or HTx
63 (7); 0.8 10 (21); 2.5 <0.001
SD or MVA 126 (14); 1.7 10 (21); 2.5 <0.001
ICD implantation 155 (17.6); 2.3 10 (21); 2.5 0.556
Death from
unknown cause
64 (7); 0.8 1 (2); 0.2 0.178
HF indicates heart failure; HTx, heart transplant; ICD, implantable cardioverter-
deﬁbrillator; MVA, major ventricular arrhythmias; SD, sudden death.
Figure 2. Rates of long-term survival free from D/HTx (A), DHF/HTx (B), and from SD/MVA (C) in 47 pediatric (solid line) vs 141 adult patients
(dotted line) matched in a 1:3 ratio after adjustment for baseline differences between the 2 subgroups. D/HTx indicates death or heart
transplantation; DHF/HTx, heart-failure death or heart transplantation; SD/MVA, sudden death or major ventricular arrhythmias.
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duration of HF symptoms. This could be due to having an
earlier diagnosis, which may be partially explained by a
systematic and detailed collection of familial history of the
probands and thus the earlier screening of relatives.
Despite these differences at baseline, both populations
share similar long-term clinical and echocardiographic pro-
gression. This may suggest a quicker progression of DCM in
younger patients. As seen previously, our pediatric population
had a signiﬁcantly poorer long-term outcome compared with
adults. All analyzed combined end points (ie, death/HTx,
death from HF/HTx, and sudden death/MVA) had higher
incidence in the pediatric population, even after adjustment
for baseline differences between groups. The long-term
incidence of death/HTx in the pediatric population reached
5 events per 100 patients per year, which is markedly higher
than 3.4 events per 100 patients per year in the adult
population. These event rates are similar to those reported in
the United States and Australia.5,6 Furthermore, the survival
rate curves of both populations start to diverge early after the
ﬁrst evaluation and progressively increase the survival gap in
the long term. This was particularly evident considering the
combined end point of death/HTx (82% versus 98% in children
versus adults at 1-year follow-up). These issues highlight the
aggressiveness of DCM in pediatric cases. Finally, the onset
of disease at an age <18 years clearly emerged as a risk
factor for all combined end points (Figure 3). This under-
scores the relevant role of pediatric age for short- and long-
term management of DCM.
These results apparently contrast with the known beneﬁ-
cial effects on the prognosis from familial screening. The
latter usually allows earlier diagnosis, often at a less severe
stage of the disease, and subsequent benign outcome.19 One
could argue that familial screening is useful for more
accurately managing the disease with tighter and more
aggressive follow-up when DCM is discovered at a pediatric
age. In adults, familial screening allows diagnosis at an earlier
stage of the disease, with a consequently better long-term
outcome.
The Arrhythmic Burden
Notably, in our study, the poorer prognosis in pediatric cases
resulted not only from the progression of HF and HTx but also
from arrhythmic events (Figures 2C and 3C). In the current
literature, much more attention has been paid to HF than to
arrhythmias in pediatric DCM patients. Nevertheless, an
important arrhythmic proﬁle in the pediatric patients com-
pared with the adults clearly emerged in this study. This topic
highlights a challenging issue in the management of DCM:
whether to implant an implantable cardioverter-deﬁbrillator
for primary prevention in children. The current HF pediatric
guidelines10 recommend this procedure for pediatric DCM
patients with unexplained syncope and at least moderate left
ventricular dysfunction (class of recommendation IIa, level of
evidence C) or with LVEF <35% and NYHA class II–III (class of
recommendation IIb, level of evidence C). They also recom-
mend this procedure for adolescent patients with a familial
cardiomyopathy associated with sudden death or for younger
patients, considering the risk–beneﬁt ratio and technical
issues (class of recommendation IIa, level of evidence C). The
low level of evidence for the guidelines suggests the ethical
and technical difﬁculty of this decision and the necessity of
risk stratiﬁcation models. Some models have been proposed
previously to identify implantable cardioverter-deﬁbrillator
candidates among children. In particular, a left ventricle
thinning and dilation ratio, diagnosis before age 13 to
Figure 3. Effect of age on outcome measurements. Pediatric age (ie, <18 years) was associated with increasing risk of all major events: D/
HTx (A), DHF/HTx (B), SD/MVA (C). D/HTx indicates death or heart transplantation; DHF/HTx, heart-failure death or heart transplantation; SD/
MVA, sudden death or major ventricular arrhythmias.
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14 years, and use of antiarrhythmic therapy within 1 month
of diagnosis emerged as predictors of sudden cardiac death20;
however, no univocal statement currently exists on this topic
in the literature. The identiﬁcation of predictors of sudden
death and MVA in pediatric DCM patients was beyond the
scope of our study because of the limited number of events.
Interestingly, at univariate analysis, family history positive for
DCM emerged as the only signiﬁcant predictor of arrhythmic
events in the pediatric population. This could suggest that
some clusters of gene mutations have an important role in
inducing speciﬁc arrhythmic phenotypes. Future studies are
needed for the investigation of such a hypothesis.
DCM at Pediatric Age: A Distinct Disease
The reasons for the relatively poor outcome in pediatric DCM
patients remain largely unknown. Most cases are idiopathic,
followed by familial forms3; therefore, pediatric forms may be
caused by particularly aggressive genetic mutations leading to
rapidly progressive disease. Accordingly, our study showed
twice the prevalence of familial forms of DCM in the pediatric
population compared with the adult patients (34.8% versus
17.5%), encouraging genetic screening in these patients and
their relatives. In some cases, a positive result may inﬂuence
clinical management, as in the presence of lamin A/C (LMNA)
mutations.21,22 In other cases, the discovery of a mutation
has no impact on the clinical management of the disease
because, currently, wide genotype–phenotype correlation
data are still lacking. Furthermore, it is known that active
myocarditis in children is more aggressive than in adults,
probably caused by a predominant immune response.23
Consequently, postinﬂammatory DCM in children is also
likely to be more severe, and more aggressive follow-up and
therapeutic strategies are advised.
Finally, the resulting independent prognostic factors that
emerged from our multivariate analysis (tolerance of beta
blocker therapy, LVEF, NYHA class) conﬁrm previous stud-
ies24,25 and reﬂect the same features that are included in adult
DCM prognostic models.2 The protective role that emerged for
beta blockers could conﬁrm their beneﬁt in pediatric as well as
adult DCM patients. Nevertheless, because of the observa-
tional nature of the present study, it is possible that beta
Table 3. Univariate and Multivariate Analysis in the Pediatric DCM Population: Predictors of Death or Heart Transplantation
HR
95% CI
P Value HR
95% CI
P ValueLower Upper Lower Upper
Sex 1.262 0.416 3.829 0.681 — — — —
BSA (for 1-U increase) 0.405 0.131 1.251 0.116 — — — —
Family history of DCM 0.798 0.33 1.930 0.616 — — — —
Family history of SD 1.102 0.249 4.887 0.898 — — — —
NYHA III to IV 2901 1.110 7.612 0.031 3.827 1.194 12.27 0.024
SBP (for 1-mm Hg increase) 0.974 0.944 1.005 0.097 — — — —
DBP, mm Hg 0.957 0.913 1.002 0.061 — — — —
LBBB (%) 4.079 0.890 18.685 0.070 — — — —
LVEDD (for 1-mm/m2 increase) 1.029 1.006 1.052 0.012 — — — —
LVESD (for 1-mm/m2 increase) 1.039 1.013 1.067 0.003 — — — —
LVEDV (for 1-mL/m2 increase) 1.019 1.010 1.029 <0.001 — — — —
LVESV (for 1-mL/m2 increase) 1.023 1.011 1.035 <0.001 — — — —
LVEF (for 1-U increase) 0.960 0.924 0.988 0.039 0.939 0.895 0.986 0.012
Moderate to severe MR 2.582 1.051 6.345 0.039 — — — —
RFP 2725 0.092 6.800 0.032 — — — —
ACEIs 0.208 0.028 1.564 0.127 — — — —
Antiarrhythmics 0.894 0.364 2.199 0.808 — — — —
Beta blockers 0.380 0.148 0.973 0.044 0.082 0.021 0.323 0.000
Enrollment period (before 2000) 3.335 0.411 27.028 0.259 — — — —
Em dash indicates no data. ACEI indicates angiotensin-converting enzyme inhibitor; BSA, body surface area; DBP, diastolic blood pressure; DCM, dilated cardiomyopathy; HR, hazard ratio;
LBBB, left bundle-branch block; LVEDD, left ventricular end-diastolic diameter; LVEDV, left ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESD, left ventricular
end-systolic diameter; LVESV, left ventricular end-systolic volume; MR mitral regurgitation; NYHA, New York heart Association; RFP, restrictive ﬁlling pattern (left ventricle); SBP, systolic
blood pressure; SD, sudden death.
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blocker intolerance was a surrogate for advanced disease
state, and a large-scale randomized trial is needed to
deﬁnitively assess the beneﬁt of beta blockers in a pediatric
DCM population. Beta blockers are currently more widely used
in children than in previous decades. Only 5% of the pediatric
patients enrolled in the American Pediatric Cardiomyopathy
Registry received beta blockers in the 1990s compared with
18% after 2000.26 An increasing burden of studies about the
pathophysiological differences of pediatric and adult HF
mechanisms characterizes the current literature.27–29 This
contributes to our understanding of the different age-related
responses to therapy. Performing clinical trials in children with
DCM is very difﬁcult, but it appears to be the only way to
identify the most useful treatments to improve outcome.
Our population has some analogies with large-scale
observational studies in the pediatric DCM population5,6,16;
however, some notable differences have to be highlighted.
The mean age of our pediatric cohort was 15 years, which is
older than most other studies on DCM in children. Moreover,
there were higher proportions of familial and male cases.
These differences should be explained by the fact that ours is
a cardiomyopathy referral center that is mostly used to
evaluate patients that are affected by idiopathic DCM, without
known causes and with an important genetic–familial or
postmyocarditis background and rarely associated with
congenital syndromes or neuromuscular diseases. In this
sense, the comparison with the adult population was not
previously reported and appears to be particularly relevant to
the clinical management of such patients. Another relevant
discrepancy concerns the prognostic longitudinal trends that
are shown in the present study. In our population, there
appears to be a continued risk of death or transplant after
1 year of follow-up after enrollment; that characteristic is
different from other pediatric DCM international reg-
istries.5,6,16 It is particularly interesting and is probably
related to the above-mentioned characteristics of idiopathic
DCM enrolled in the present registry. These characteristics
revealed a particularly aggressive nature of the disease in the
short and long terms in children more than in adults.
Table 4. Univariate Analysis in the Pediatric DCM Population:
Predictors of Death from Heart Failure or Heart
Transplantation
HR
95% CI
P ValueLower Upper
Sex 1.548 0.192 12.509 0.682
BSA (for 1-U increase) 0.193 0.053 0.703 0.013
Family history of DCM 1.011 0.284 3.595 0.987
Family history of SD 1.137 0.135 9.587 0.906
NYHA III–IV 6573 1.882 22.963 0.003
SBP (for 1-mm Hg increase) 0.914 0.867 0.964 0.001
DBP, mm Hg 0.955 0.893 1.020 0.172
LBBB (%) 5.204 0.578 46.856 0.141
LVEDD (for 1-mm/m2 increase) 1.041 1.013 1.069 0.003
LVESD (for 1-mm/m2 increase) 1.054 1.020 1.089 0.002
LVEDV (for 1-mL/m2 increase) 1.021 1.008 1.035 0.002
LVESV (for 1-mL/m2 increase) 1.027 1.010 1.044 0.002
LVEF (for 1-U increase) 0.944 0.893 0.999 0.046
Moderate to severe MR 5.849 1.637 20.906 0.007
RFP 4.412 1.137 17.118 0.032
ACEIs 26.093 0.013 52.214 0.400
Antiarrhythmics 0.699 0.179 2.725 0.605
Beta blockers 0.773 0.159 3.757 0.749
ACEI indicates angiotensin-converting enzyme inhibitor; BSA, body surface area; DBP,
diastolic blood pressure; DCM, dilated cardiomyopathy; HR, hazard ratio; LBBB, left
bundle branch block; LVEDD, left ventricular end-diastolic diameter; LVEDV, left
ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESD, left
ventricular end-systolic diameter; LVESV, left ventricular end-systolic volume; MR mitral
regurgitation; NYHA, New York heart Association; RFP, restrictive ﬁlling pattern (left
ventricle); SBP, systolic blood pressure; SD, sudden death.
Table 5. Univariate in the Pediatric DCM Population:
Predictors of Major Ventricular Arrhythmias or Sudden Death
HR
95% CI
P ValueLower Upper
Sex 0.852 0.180 4.039 0.840
BSA (for 1-U increase) 3.578 0.226 56.574 0.365
Family history of DCM 3.794 1.224 14.744 0.045
Family history of SD 3.051 0.556 16.760 0.199
NYHA III–IV 0.678 0.085 5.395 0.714
SBP (for 1-mm Hg increase) 0.987 0.945 1.031 0.549
DBP, mm Hg 0.957 0.894 1.024 0.204
LBBB (%) 0.046 0.001 49.29 0.744
LVEDD (for 1-mm/m2 increase) 0.994 0.934 1.059 0.858
LVESD (for 1-mm/m2 increase) 1.010 0.957 1.065 0.728
LVEDV (for 1-mL/m2 increase) 1.016 0.999 1.032 0.059
LVESV (for 1-mL/m2 increase) 1.018 0.999 1.036 0.063
LVEF (for 1-U increase) 0.956 0.907 1.008 0.096
Moderate to severe MR 0.508 0.064 4.041 0.522
RFP 1.457 0.408 5.196 0.562
ACEIs 2.472 0.266 17.396 0.472
Antiarrhythmics 3.650 0.938 14.209 0.062
Beta blockers 0.711 0.147 3.443 0.671
ACEI indicates angiotensin-converting enzyme inhibitor; BSA, body surface area; DBP,
diastolic blood pressure; DCM, dilated cardiomyopathy; HR, hazard ratio; LBBB, left
bundle-branch block; LVEDD, left ventricular end-diastolic diameter; LVEDV, left
ventricular end-diastolic volume; LVEF, left ventricular ejection fraction; LVESD, left
ventricular end-systolic diameter; LVESV, left ventricular end-systolic volume; MR mitral
regurgitation; NYHA, New York heart Association; RFP, restrictive ﬁlling pattern (left
ventricle); SBP, systolic blood pressure; SD, sudden death.
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Limitations
Our study has some limitations. First, selection biases relate
to its retrospective and registry-based nature. Moreover, the
rarity of this disease among the pediatric population in
general inﬂuenced the size of the samples studied. To
overcome this issue, a “case-control–like” strategy was
achieved by means of a random matching procedure. Another
limitation concerns the availability of long-term follow-up data,
which were not complete for all patients because of the event
rates and censoring mechanism. Consequently, the long-term
trends of the main clinical and echocardiographic features
shown in Figure 1 should be interpreted with caution and
conﬁrmed by future studies that go on for a longer time. In our
opinion, however, the comparison with the adult population
(affected by the same limit) is reliable. For most of the
patients, the genetic data and cardiac magnetic resonance
information were lacking, thus we could not include these
data in our analyses. Because of the limited number of events,
uni- and multivariable analyses were presented mainly for
exploratory purposes and should be conﬁrmed in larger
series. Future focused studies are warranted to assess the
possible prognostic role of these tools in pediatric populations
compared with adults. Finally, we included HTx in the
composite end point even though it is not a fatal event. In
our opinion, it remains a major event in the natural history of
DCM that has the same impact of death in the prognostic
evaluation of the disease, especially considering that only
urgent HTx examples were included.
Conclusions
The data of this Italian registry suggest that pediatric DCM
patients are rare but have a worse outcome than adult
patients. This is despite similar treatments, a less advanced
stage of the disease at baseline in children, and similar clinical
and echocardiographic long-term progression. These ﬁndings
were further conﬁrmed after adjusting for other covariates
that were signiﬁcantly different from adults at the time of the
onset of the disease. Finally, pediatric age emerged as an
important prognostic predictor of both death from HF and life-
threatening ventricular arrhythmias.
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None.
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